Rheumatoid Arthritis-Associated Interstitial Lung Disease: Current Concepts

Area of Science:

• Rheumatology
• Pulmonology
• Immunology

Background:

• Rheumatoid arthritis (RA) can lead to extra-articular complications, notably interstitial lung disease (ILD), a major cause of morbidity and mortality.
• Prevalence of RA-ILD varies based on diagnostic criteria, and the progression from subclinical to end-stage fibrotic lung disease remains unclear.
• Current therapeutic strategies for RA-ILD are not well-defined due to limited understanding of its natural history and pathogenesis.

Purpose of the Study:

• To review the current understanding of rheumatoid arthritis-associated interstitial lung disease (RA-ILD).
• To explore risk factors, pathogenesis, and potential therapeutic strategies for RA-ILD.
• To address the unresolved question of whether early RA-ILD precedes advanced fibrotic lung disease.

Main Methods:

• Review of clinico-epidemiological studies identifying risk factors for RA-ILD progression.
• Analysis of molecular and serological markers for understanding RA-ILD pathogenesis.
• Evaluation of case series and cohort studies on treatment options for RA-ILD.

Main Results:

• Key risk factors for RA-ILD progression have been identified through clinico-epidemiological studies.
• Specific molecular and serological markers enhance understanding of RA-ILD pathogenesis and enable predictive biomarker profiling.
• Rituximab and other biological agents show promise as potential treatments for RA-ILD, based on preliminary studies.

Conclusions:

• RA-ILD remains a significant contributor to morbidity and mortality in rheumatoid arthritis patients.
• Further understanding of RA-ILD pathogenesis and the natural history of subclinical disease is crucial.
• Development of refined therapeutic strategies for RA-ILD is anticipated with ongoing research.